Soleno - SLNO Quarterly EPS earnings growth

Soleno Therapeutics Corp - graphic logo of issuer SLNO

The experienced management of Soleno Therapeutics (SLNO) has laid the groundwork for the commercialization of a drug for a rare genetic disorder, although business success depends on FDA approval and DCCR insurance coverage. The quarterly EPS history visualizes these expectations, where the 162.30 metric reflects current dynamics. The readiness of certified facilities to scale production confirms the company's excellent technical potential.

Soleno Therapeutics, Inc. (SLNO) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 05/30/2026

Financial and market metric breakdowns for Soleno Therapeutics (SLNO)

- share price and consensus valuation forecast:
Analysis of all company metrics:Soleno Therapeutics
Manufactured product of Soleno Therapeutics Corp

For the biotech startup Soleno Therapeutics (SLNO), profit dynamics reflect the cost efficiency of developing drugs for rare diseases. This metric calculates the percentage change in earnings per share compared to the same quarter of the previous year. By analyzing the quarterly EPS growth marker, an investor can see the actual financial results of regulatory successes. For Soleno Therapeutics, growth in this indicator often correlates with passing FDA milestones. A stable upward trend confirms the commercial viability of the business model.

Competitors of Soleno Therapeutics (SLNO)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months rezolutebio.com (RZLT)|Year-over-year net earnings per share growth for the last 12 months lexpharma.com LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS